Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases
暂无分享,去创建一个
[1] J. Bayascas,et al. PDK1: the major transducer of PI 3-kinase actions. , 2010, Current topics in microbiology and immunology.
[2] Carlo Rago,et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.
[3] N. Verdaguer,et al. Ca2+ bridges the C2 membrane‐binding domain of protein kinase Cα directly to phosphatidylserine , 1999 .
[4] J. Engelman,et al. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3 , 2010, Oncogene.
[5] M. Lemmon,et al. Determining selectivity of phosphoinositide-binding domains. , 2006, Methods.
[6] Fabrice Gorrec,et al. The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. , 2010, Nature chemical biology.
[7] Yosef Yarden,et al. Roles for growth factors in cancer progression. , 2010, Physiology.
[8] B. González,et al. Structure of a human inositol 1,4,5-trisphosphate 3-kinase: substrate binding reveals why it is not a phosphoinositide 3-kinase. , 2004, Molecular cell.
[9] Roger L. Williams,et al. Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism , 2011, Molecular cell.
[10] Roger L. Williams,et al. Mapping the Phospholipid-binding Surface and Translocation Determinants of the C2 Domain from Cytosolic Phospholipase A2 * , 1999, The Journal of Biological Chemistry.
[11] N. Verdaguer,et al. Ca(2+) bridges the C2 membrane-binding domain of protein kinase Calpha directly to phosphatidylserine. , 1999, The EMBO journal.
[12] K. Kinzler,et al. A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane , 2009, Proceedings of the National Academy of Sciences.
[13] B. Margolis,et al. Phosphatidylinositol 3′‐kinase is activated by association with IRS‐1 during insulin stimulation. , 1992, The EMBO journal.
[14] Bert Vogelstein,et al. The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.
[15] R. Owens,et al. Generation of baculovirus vectors for the high‐throughput production of proteins in insect cells , 2008, Biotechnology and bioengineering.
[16] Lewis C. Cantley,et al. AKT/PKB Signaling: Navigating Downstream , 2007, Cell.
[17] Jeffrey A. Engelman,et al. Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.
[18] Jeffrey Wyckoff,et al. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. , 2009, Cancer research.
[19] T. Franke,et al. PI3K/Akt: getting it right matters , 2008, Oncogene.
[20] Li Zhao,et al. Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms , 2008, Proceedings of the National Academy of Sciences.
[21] M. Zvelebil,et al. Activation Loop Sequences Confer Substrate Specificity to Phosphoinositide 3-Kinase α (PI3Kα) , 2001, The Journal of Biological Chemistry.
[22] Wonhwa Cho,et al. Membrane-protein interactions in cell signaling and membrane trafficking. , 2005, Annual review of biophysics and biomolecular structure.
[23] W. Cho,et al. The Molecular Basis of Differential Subcellular Localization of C2 Domains of Protein Kinase C-α and Group IVa Cytosolic Phospholipase A2 * , 2003, The Journal of Biological Chemistry.
[24] J. Backer,et al. Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. , 1998, The Journal of biological chemistry.
[25] Roger L. Williams,et al. Dynamics of the Phosphoinositide 3-Kinase p110δ Interaction with p85α and Membranes Reveals Aspects of Regulation Distinct from p110α , 2011, Structure.
[26] S. Egan,et al. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. , 2011, Cancer research.
[27] N. Pannu,et al. REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.
[28] N. Verdaguer,et al. Structural and mechanistic insights into the association of PKCα-C2 domain to PtdIns(4,5)P2 , 2009, Proceedings of the National Academy of Sciences.
[29] Ralph Weissleder,et al. Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.
[30] L. Cantley,et al. PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.
[31] K. Shokat,et al. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. , 2008, Cancer research.
[32] Bernd Giese,et al. Targeting phosphoinositide 3-kinase: moving towards therapy. , 2008, Biochimica et biophysica acta.
[33] Guojun Wu,et al. Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells , 2008, Breast Cancer Research and Treatment.
[34] M. Lemmon,et al. Membrane recognition by phospholipid-binding domains , 2008, Nature Reviews Molecular Cell Biology.
[35] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[36] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[37] G. Prestwich,et al. Competitive fluorescence polarization assays for the detection of phosphoinositide kinase and phosphatase activity. , 2003, Combinatorial chemistry & high throughput screening.
[38] M. Loda,et al. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[39] Yiling Lu,et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.
[40] D. Sgroi,et al. A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas , 2011, Clinical Cancer Research.
[41] Pier Paolo Pandolfi,et al. The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.
[42] M. Loda,et al. The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells , 2005 .
[43] R. Cardiff,et al. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. , 2011, Cancer research.
[44] K. Shokat,et al. Shaping Development of Autophagy Inhibitors with the Structure of the Lipid Kinase Vps34 , 2010, Science.
[45] I. Jones,et al. Improving baculovirus recombination. , 2003, Nucleic acids research.
[46] Marc-André Elsliger,et al. Rare cancer-specific mutations in PIK3CA show gain of function , 2007, Proceedings of the National Academy of Sciences.
[47] R. Copeland,et al. Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase , 2008 .
[48] L. Cantley,et al. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. , 1993, The Journal of biological chemistry.
[49] J. Gills,et al. Perifosine: Update on a novel Akt inhibitor , 2009, Current oncology reports.
[50] Yuval Inbar,et al. Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit , 2007, Science.
[51] S. Baker,et al. PTEN and the PI3-kinase pathway in cancer. , 2009, Annual review of pathology.
[52] R. Copeland,et al. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. , 2008, The Biochemical journal.
[53] M. Girvin,et al. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110α and are disrupted in oncogenic p85 mutants , 2009, Proceedings of the National Academy of Sciences.
[54] Bert Vogelstein,et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. , 2007, Science.
[55] T. Kawabe,et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. , 2005, Cancer research.
[56] Geoffrey J. Barton,et al. Jalview Version 2—a multiple sequence alignment editor and analysis workbench , 2009, Bioinform..
[57] B. Peters,et al. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. , 2009, Cancer cell.
[58] Christian Ried,et al. Structural insights into phosphoinositide 3-kinase catalysis and signalling , 1999, Nature.
[59] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[60] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .